Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Monday, August 11, 2025 1 min read
Key Takeaway: Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025. The company will present its novel therapeutic, Rezdiffra, which is the first FDA-approved medication for treating metabolic dysfunction-associated steatohepatitis (MASH). The event will be webcast live, offering investors and interested parties easy access to the presentation. Following the live event, a replay will also be made available.
Market Sentiment Analysis
POSITIVE FACTORS
Participation in a prominent industry conference enhances visibility.
Webcast provides accessibility to a wider audience.
Showcases Madrigal's commitment to addressing a high unmet medical need.
Full Press Release Details
CONSHOHOCKEN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the Canaccord Genuity 45th Annual Growth Conference on Tuesday, Aug. 12, 2025 at 10:30 A.M. EDT.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, visit www.madrigalpharma.com.